AlphAIalphai — Financial news for AI agents
MoomooAPR 13 min read$TOVX

Theriva Biologics Raised to Buy From Hold by Maxim Group

Maxim Group has upgraded Theriva Biologics (NYSE:TBIO) from a Hold rating to a Buy rating. The firm also set a new price target of $9.00 for the company's stock. This upgrade suggests a positive outlook on Theriva Biologics' future performance.

Original reporting
Moomoo
Published Apr 1, 2026, 9:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 1, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$TOVX
Neutral
low confidence
Mentioned
$TOVX
alphai data visualization · based on Moomoo
Decision brief

The 30-second read

$TOVXNeutralLow
01

Why it matters

While the upgrade is positive for Theriva Biologics, its influence on TOVX is minimal due to low relevance. The broader biotech sector may experience slight positive sentiment, but specific impact on TOVX is unlikely.

02

Market read

The news is relevant primarily to investors in Theriva Biologics and the biotech sector, with limited direct impact on other stocks like TOVX.

03

What to watch

Potential sector rotation or macroeconomic factors could overshadow company-specific news, limiting the impact on TOVX.

Timing: short-term

Background

Maxim Group's upgrade of Theriva Biologics from Hold to Buy indicates a positive outlook on the company's future performance, driven by anticipated growth or positive developments.

Company-level read

Ticker impact

$TOVXNeutralLow confidence
Context

Low relevance due to minimal sentiment impact and limited connection to the primary news.

Expected impact

Limited or negligible impact on TOVX; no significant price movement expected.

Evidence & confidence

TOVX has a low relevance score (0.3067), indicating limited direct connection to the news. Its neutral sentiment and low relevance suggest minimal influence on its price.

Market effects

Sector

Potential positive sentiment in the biotech and life sciences sectors due to news about Theriva Biologics.

Regional

Limited regional impact; primarily US-focused news.

Global

Minimal global market relevance; specific to biotech sector.

Counterpoint

What could challenge this read

The upgrade of Theriva Biologics may not translate into broader biotech sector gains, and TOVX could remain unaffected or even decline if sector sentiment shifts.

Key entities

  • Company
    Theriva Biologics

    A biotechnology company focused on developing innovative therapies.

  • Financial Firm
    Maxim Group

    An investment firm that upgraded Theriva Biologics.

Read at source← All news

Related articles

AUG 11
$TOVXMed

Theriva Biologics, Inc. (TOVX): Results of Operations and Financial Condition

Theriva Biologics, Inc. (TOVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results – First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve tr

SEC EDGAR 8-K4 min
AUG 6
$TOVXMed

Theriva Biologics, Inc.: Theriva Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patient

Theriva Biologics (NYSE American: TOVX) said the first patient was dosed in its VIRAGE2 Phase 2a trial testing more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) in first-line metastatic pancreatic ductal adenocarcinoma with gemcitabine/nab-paclitaxel. Enrollment is expected to finish in H2 2026, with initial data in Q3 2027.

finanznachrichten.de4 min
JUL 7
$TOVXMedAI 8/10

Theriva Biologics, Inc.: Theriva Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) i

Theriva Biologics (NYSE American: TOVX) said Spain’s AEMPS authorized it to start the VIRAGE2 Phase 2a trial of zabilugene almadenorepvec (VCN-01) with gemcitabine/nab-paclitaxel in newly diagnosed metastatic pancreatic cancer. VIRAGE2 will test feasibility of at least 3 VCN-01 doses 2 months apart in 6 patients; primary endpoints are safety and VCN-01 viral genome levels.

finanznachrichten.de2 min
SEP 8
$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min